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NOS2-deficient mice with 
hypoxic necrotizing lung lesions 
predict outcomes of tuberculosis 
chemotherapy in humans
Martin Gengenbacher1,2, Maria A. Duque-Correa1,7, Peggy Kaiser1, Stefanie Schuerer1, Doris 
Lazar1, Ulrike Zedler1, Stephen T. Reece1,8, Amit Nayyar3,9, Stewart T. Cole4, Vadim Makarov5, 
Clifton E. Barry III3,6, Véronique Dartois2 & Stefan H. E. Kaufmann  1
During active TB in humans a spectrum of pulmonary granulomas with central necrosis and hypoxia 
exists. BALB/c mice, predominantly used in TB drug development, do not reproduce this complex 
pathology thereby inaccurately predicting clinical outcome. We found that Nos2−/− mice incapable 
of NO-production in immune cells as microbial defence uniformly develop hypoxic necrotizing 
lung lesions, widely observed in human TB. To study the impact of hypoxic necrosis on the efficacy 
of antimycobacterials and drug candidates, we subjected Nos2−/− mice with TB to monotherapy 
before or after establishment of human-like pathology. Isoniazid induced a drug-tolerant persister 
population only when necrotic lesions were present. Rifapentine was more potent than rifampin prior to 
development of human-like pathology and equally potent thereafter, in agreement with recent clinical 
trials. Pretomanid, delamanid and the pre-clinical candidate BTZ043 were bactericidal independent 
of pulmonary pathology. Linezolid was bacteriostatic in TB-infected Nos2−/− mice but significantly 
improved lung pathology. Hypoxic necrotizing lesions rendered moxifloxacin less active. In conclusion, 
Nos2−/− mice are a predictive TB drug development tool owing to their consistent development of 
human-like pathology.
Tuberculosis (TB) is a global health threat further worsened by increasing incidences of drug resistance and 
HIV co-infection1. New drugs to combat resistant TB and to shorten the current 6 to 9 month standard-of-care 
chemotherapy are urgently needed. In most cases, infection starts in the lungs where Mycobacterium tuberculosis 
induces well-structured granulomas composed of various hematopoietic cells in which the pathogen is con-
tained2, 3. During progression to active disease, infected macrophages and neutrophils undergo necrosis at the 
core of these structure, resulting in the formation of a hypoxic caseum2.18F-fluorodeoxyglucose positron emis-
sion tomography/computed tomography has revealed that pulmonary TB is a highly dynamic disease: coexisting 
inflammatory hotspots in lungs of TB patients increase in size, shrink or even resolve over time while others are 
newly formed4, 5. Recent studies have indicated that pro- and anti-inflammatory signals are spatially segregated 
within granulomas of humans suggesting that granuloma formation in TB is a direct consequence of the local 
activity of inflammatory pathways6.
Among the available animal models, non-human primates mirror the facets of human TB best, but broad 
application is hampered by prohibitive cost and ethical concerns. To date, mice remain the most widely used 
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model for pre-clinical TB drug development. However, upon M. tuberculosis infection, small rodents develop a 
more uniform type of unstructured lesions that lack central necrosis and hypoxia7, two key features of human 
granulomas. Commonly employed strains such as BALB/c mice may therefore inaccurately predict the outcome 
of new drug candidates and treatment regimens in humans, as emphasized by the disappointing results of three 
large and costly clinical trials8–10. Bridging the disconnect between pre-clinical mouse models and TB patients is 
therefore mandatory for accelerated drug development.
The murine supersusceptibility to tuberculosis 1 (sst1) locus has been found to prevent formation of necrotic 
lesions in mice. The intracellular pathogen resistance 1 (Ipr1)-protein encoded within this locus can switch the 
molecular program of infected macrophages from necrosis to apoptosis11. C3HeB/FeJ mice lacking a functional 
ipr1 gene develop large pulmonary lung lesions with central caseous necrosis during M. tuberculosis infection12. 
This model has been used in several studies to evaluate monotherapy with anti-TB drugs and clinically relevant 
drug regimens12–17. In-depth pathological characterization of M. tuberculosis-infected C3HeB/FeJ mice revealed 
multiple lung lesion types which are either large, caseous and necrotic and characterized by neutrophil-dominated 
granulocytic pneumonia or which reflect unstructured lesions as observed in BALB/c mice18. C3HeB/FeJ mice 
with a predominance of caseous necrotic lesions versus cellular inflammatory lesions (‘BALB/c-type’) respond 
differently to chemotherapy14.
TB drugs need to penetrate the granuloma to act on the pathogen in different physiological states. Previous in 
vitro studies suggest that drug penetration into non-replicating M. tuberculosis is reduced19. Such non-replicating 
persisters are a difficult-to-treat population believed to reside in the unfavourable microenvironment of necrotic 
and hypoxic granulomas2. Moreover, drugs have been shown to differentially penetrate into well-structured TB 
lesions in rabbits20 and in humans21. Moxifloxacin (MXF) in particular was demonstrated to diffuse relatively 
poorly into central caseum – a finding which can explain the failure of this drug to shorten treatment duration in 
the clinic9, 10, 21. Thus, a substantial body of evidence suggests that different granuloma pathologies as they occur 
in TB patients impact treatment outcomes.
The inducible oxygen-dependent host enzyme nitric oxide synthase-2 (NOS2) counteracts microbial intrud-
ers by means of NO production. Consequently, Nos2−/− mice deficient for this defence mechanism are exquisitely 
susceptible to bacterial infections including TB22. Our previous work demonstrated that M. tuberculosis-infected 
Nos2−/− mice develop solid structured granulomas in which central necrosis followed by hypoxia can be induced 
by neutralization of interferon-gamma or tumour necrosis factor alpha (TNF-α)23, 24. The human-like granuloma 
pathology of Nos2−/− mice prompted us to harness this model for evaluation of TB monotherapy with first-line 
drugs and new candidates under development, to examine the direct impact of necrosis and hypoxia on outcome 
of chemotherapy.
Results
Dermal M. tuberculosis infection of Nos2−/− mice consistently induces lung lesions with central 
necrosis and hypoxia. Previously, we demonstrated the capacity of Nos2−/− mice to develop a TB patient-
like pulmonary pathology upon dermal M. tuberculosis infection that includes central necrosis and hypoxia in 
structured lesions23, 24. In order to harness Nos2−/− mice for TB drug development as schematically depicted 
in Fig. 1a, the temporal onset of patient-like pathology needed to be defined. We dermally infected groups of 
mice, neutralized the TNF-α response at 14 and 21 days post-infection, and assessed bacterial burden (supe-
rior, middle, inferior and post-caval lobe) and pathology (left lobe) of lungs at days 42, 56, 70 and 84. The total 
number of bacilli residing in lungs of Nos2−/− mice was 105 colony forming units (c.f.u.) at day 42 and increased 
to 107 c.f.u. by day 70 after which the bacterial burden remained stable on a level comparable to low-dose-in-
fected BALB/c mice (Fig. 1b)25. Consecutive thin sections of the fixed and paraffin-embedded left lung lobe were 
stained with H&E or used for immunohistochemistry to visualize hypoxic areas. The average number of lesions 
per section moderately increased from 6.3 at day 42 to 8.5 at the end of the experiment (Fig. 1c). In contrast, the 
numbers of necrotic and hypoxic lesions were negligible 42 days post-infection, became apparent at day 56 and 
further increased until 84 days, when roughly 75% of all lesions showed patient-like pathology including necrosis 
and hypoxia (Fig. 1d,e). Importantly, lung lesions of all mice collectively and co-ordinately developed advanced 
pathology in a distinctively narrow time window. We concluded that the response of hypoxic necrotizing pulmo-
nary lesions to TB chemotherapy in Nos2−/− mice could be assessed by initiating drug treatment at day 42 in the 
control group and after onset of necrosis and hypoxia at day 56 in the study group (Fig. 1a).
Pulmonary pathology of M. tuberculosis-infected Nos2−/− mice includes central necrosis, 
hypoxia, foamy macrophages and peripheral fibrosis. With few exceptions, lung lesions 42 days 
after infection appeared non-necrotizing and not hypoxic (Supplementary Fig. S1a). At day 56, about 50% of all 
lesions showed signs of central necrosis of which half were hypoxic (Supplementary Fig. S1a,b). Pimonidazole 
adducts formed under oxygen limitation often appeared in regions with circular shape. (Supplementary Fig. S1a, 
lower row, Supplementary Fig. S1b, middle panel). Acid-fast staining of lung sections revealed a large number of 
M. tuberculosis bacilli in lesion centres at onset of necrosis (Supplementary Fig. S1b, right panel). From day 70 
onwards, lighter stained central areas of lung lesions were enlarged and sharply separated from the surrounding 
granulomatous inflammatory infiltrates indicating advanced necrosis (Supplementary Fig. S1a, upper panel).
On day 84 we observed advanced necrosis characterized by enlarged areas of central tissue consolidation, 
fibrous encapsulation and caseation of lesions on day 84, which are pathological late-stage correlates of human 
TB (Fig. 2a,b). The fibrous capsule was separated from the central caseum by a layer of infected cells presumably 
foamy macrophages (Fig. 2c,d) as seen in human granulomas26. In contrast to other murine TB models, lung 
lesions of Nos2−/− mice collectively and coordinately developed hypoxic necrotizing lung lesions allowing to 
assess the direct impact of TB chemotherapy on patient-like pathology by initiating drug treatment at different 
time points (Fig. 1a).
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Efficacy of isoniazid monotherapy is reduced in hypoxic necrotizing lesions. The first-line TB 
drug isoniazid (INH) targets mycobacterial cell wall biosynthesis and kills growing M. tuberculosis but is well 
tolerated by the non-replicating pathogen in vitro27, 28 and in vivo29. INH at a dose of 25 mg/kg was strongly 
bactericidal in Nos2−/− mice when chemotherapy was started 42 days post-infection (Fig. 3a). The initial steep 
decline in pulmonary bacterial burden slowed down after 14 days of drug treatment revealing a bi-phasic profile 
comparable to observations made in BALB/c mice (Fig. 3a)13. In contrast, when INH administration in Nos2−/− 
mice was initiated after onset of necrosis and hypoxia the bacterial load declined by 1.62 log c.f.u. during the 
first 2 weeks of treatment and remained an a comparable level thereafter (Fig. 3a). Development of genetic drug 
resistance that might have prevented further decline in c.f.u. could be ruled out since plating lung homogenates 
on agar containing 4 μg/ml INH at the end of the experiment did not result in colony formation. We conclude that 
Figure 1. Temporal development of hypoxic necrotizing lung lesions in Nos2−/− mice upon dermal M. 
tuberculosis infection. (a) Schematic representation of study design. (b) Infection dose (day 0) and bacterial 
burden in lungs at 42, 56, 70 and 84 days post-intradermal M. tuberculosis infection determined by plating 
serial dilutions of lung homogenates on agar. n = 10, representative of 2 independent experiments. (c–e) 
Histopathological evaluation of sections obtained from the entire left lung lobe of M. tuberculosis-infected 
Nos2−/− mice at designated time points. Consecutive sections were stained with H&E to quantify lesions (c) and 
necrosis (d). Hypoxic lesions were identified by detection of pimonidazole adducts (Supplementary Fig. S1e), 
n = 5, representative of 3 independent experiments. Data are represented as means ± s.d. TNF-α, tumour 
necrosis factor alpha.
Figure 2. Nos2−/− mice with TB form pulmonary caseous lesions with fibrous encapsulation and infected cells. 
(a–d) Lung sections of Nos2−/− mice 84 days post-intradermal M. tuberculosis infection. H&E, Trichrome and 
Ellis’ acid fast staining of caseous lesions are shown. (a) The caseous center is separated from the fibrous cuff 
consisting of blue-stained newly formed collagen fibers (b) by a layer of lighter-appearing cells (c) presumably 
including infected foamy macrophages. (d) Acid fast rod-shaped M. tuberculosis bacilli are stained pink 
(arrows). Abbreviations: C, caseation; I, intersection; FC, fibrous cuff; H&E, haematoxylin & eosin.
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a drug-tolerant persister population of M. tuberculosis developed in hypoxic necrotizing lung lesions of Nos2−/− 
mice under INH pressure.
Comparable bactericidal activity of rifampin and rifapentine. Rifamycins inhibit RNA biosynthesis 
and are a cornerstone of current TB chemotherapy30. While rifampin (RIF) has been in clinical use for decades, its 
derivative rifapentine (RPT) showed higher potency and greater drug exposure in mice, thereby raising hopes for 
shorter treatment over RIF31–33. Both drugs, RIF and RPT were profoundly bactericidal in Nos2−/− mice (Fig. 3b). 
We observed a significant dose response for RIF administered at 10 or 20 mg/kg, which was only moderately 
influenced by the presence of hypoxic necrotizing lesions at treatment start. In contrast, RPT did not show a dose 
response when given at 5 and 10 mg/kg (Fig. 3b). The bacterial load of lungs in groups receiving 20 mg/kg RIF, 
5 mg/kg RPT and 10 mg/kg RPT were roughly equivalent in absence of necrosis and hypoxia (Fig. 3b, left panel). 
RIF was more active in patient-like lesions in Nos2−/− mice while RPT efficacy did not change with pathology: 
Figure 3. Impact of monotherapy on pulmonary bacterial burden in Nos2−/− mice with TB. Monotherapy for 
4 weeks was initiated at day 42 (control group) or after onset of central necrosis and hypoxia in lung lesions 
at day 56 (study group) as described in Fig. 1a. Drugs were administered by oral gavage on 6 days per week. 
Bacterial burdens in lungs were assessed by plating organ homogenates on agar. One representative dataset out 
of 2 independent experiments is shown. Data were analysed using two-way ANOVA with multicomparison 
and Tukey’s post-test. Shown are means ± s.e.m. and the log10 reduction of mean c.f.u. counts as compared 
to animals prior to chemotherapy (summarized in Supplementary Table S1), n = 5, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. (a) isoniazid, 25 mg/kg. (b) rifampin, 10 mg/kg and 20 mg/kg; rifapentine, 5 mg/
kg and 10 mg/kg. (c) metronidazole, 400 mg/kg. (d) pretomanid, 75 mg/kg. (e) delamanid, 1 mg/kg. (f) linezolid, 
100 mg/kg. (g) moxifloxacin, 200 mg/kg. (h) BTZ043, 50 mg/kg.
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the burden of pulmonary TB at the end of the experiment was comparable in mice treated with 10 mg/kg RIF and 
10 mg/kg RPT (Fig. 3b, right panel) principally resembling clinical outcome8. Organ homogenates plated on agar 
containing either RIF or RPT did not result in any c.f.u., confirming absence of genetic drug resistance. Taken 
together, RIF and RPT had similar efficacy in Nos2−/− mice with hypoxic necrotizing lung lesions.
Pretomanid and delamanid but not metronidazole are bactericidal in hypoxic necrotizing 
lesions. The antibiotic metronidazole (MTZ) can kill non-replicating M. tuberculosis under hypoxic in vitro 
conditions, though only at very high concentrations that are hardly achieved in vivo34. Daily administration of 
400 mg/kg MTZ to Nos2−/− mice had no effect on c.f.u. recovered from lung homogenates (Fig. 3c). A minute 
reduction after onset of necrosis and hypoxia in lung lesions (Fig. 3c) may be taken as indication for a hypoxia 
induced non-replicating M. tuberculosis subpopulation. In contrast, two chemically related derivatives, pretoma-
nid (PTM) and delamanid (DLM), were bactericidal in Nos2−/− mice with or without hypoxic necrotizing lesions 
(Fig. 3d,e). PTM is in advanced clinical development and DLM has recently been approved for use in patients 
with multidrug-resistant TB. Both drugs are bactericidal for replicating and non-replicating M. tuberculosis in 
culture and in mice that do not develop hypoxic necrotizing TB lesions35, 36. Our data support further develop-
ment of PTN and DLM for TB chemotherapy.
Hypoxic necrotizing lesions render linezolid bacteriostatic, reduce activity of moxifloxacin 
and do not affect efficacy of BTZ043. The antimicrobial linezolid (LZD) is in clinical use for treat-
ment of serious infections caused by Gram-positive pathogens including vancomycin-resistant enterococci, 
methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae37. The drug is bac-
tericidal in the BALB/c mouse model of TB, in C3HeB/FeJ mice with patient-like pathology and in patients with 
extensively drug-resistant TB13, 38. At a daily dose of 100 mg/kg given to Nos2−/− mice for 4 weeks, LZD caused 
only marginal statistically insignificant reduction of lung c.f.u., as compared to treatment start (Fig. 3f). The pres-
ence of hypoxic necrotizing lesions abolished this trend suggesting bacteriostatic activity of LZD in this model 
(Fig. 3f).
The fourth generation fluoroquinolone, moxifloxacin (MXF), is broadly used for treatment of bronchitis, 
pneumonia and bacterial infections of the sinus, skin and abdomen. MXF has a high potency against M. tuber-
culosis in cultures and in mice without human-like lung pathology39. In our experiments, onset of hypoxia and 
necrosis in lung lesions of Nos2−/− mice caused a 10-fold reduction of MXF bactericidal activity (Fig. 3g), indicat-
ing a direct impact of human-like pathology on MXF activity. The benzothiazinone pre-clinical drug candidate 
BTZ043, targeting M. tuberculosis cell wall biosynthesis, has nanomolar whole-cell activity and good in vivo effi-
cacy in mice40. Unlike MFX, BTZ043 was highly potent in Nos2−/− mice regardless of patient-like lung pathology 
(Fig. 3h).
Chemotherapy alters TB lung pathology in Nos2−/−. For most drugs the impact of monotherapy on 
bacterial survival correlated fairly well with histopathological findings (Fig. 4). With the exception of MTZ, none 
of the study drugs facilitated development of advanced pathology when chemotherapy was initiated prior onset of 
hypoxia and necrosis (Fig. 4). Unlike RIF and BTZ043, the capacity of INH, RBT, PTM, DLM, LZD and MXF to 
resolve lung lesions was reduced (Fig. 4). MTZ closely resembled lesion occurrence in untreated animals and thus 
completely failed to alter pathology (Fig. 4c; Fig. 1c-d). INH, PTM, DLM and MXF maintained a small number of 
hypoxic necrotizing lesions until end of the experiment at day 84 eventually providing a niche for non-replicating 
pathogen survival (Fig. 4a,c-d,f). Only RIF and BTZ043 completely abolished hypoxia and necrosis in line with 
the strong bactericidal activity of both drugs (Fig. 3b,h; Fig. 4b,h). Intriguingly, LZD, bacteriostatic (Fig. 3f) in 
the presence of human-like lesions, significantly reduced occurrence of hypoxia, necrosis and overall numbers 
of lesions (Fig. 4f, Supplementary Fig. S2), which leaves the possibility that LZD may unfold more pronounced 
bactericidal activity after resolving advanced pathology.
Discussion
The Nos2−/− mouse model of TB evaluated here displays significantly improved lung pathology over conventional 
BALB/c mice, comprising well-structured lesions with central necrosis and hypoxia as well as peripheral fibrosis 
(Supplementary Fig S1, Fig. 2). Following dermal infection, inflammatory foci in lungs progressed towards more 
advanced pathology in all infected mice, showing first signs of central necrosis followed by hypoxia, advanced 
necrosis and finally caseation in distinct lesions (Fig. 1c-d, Fig. 2). Pimonidazole adducts as indicators of hypoxia 
frequently appeared annular in the lesional centre indicating advanced necrosis and absence of viable cells capa-
ble of metabolizing the hydroxyprobe in the innermost centre. Our model presents similarities with the C3HeB/
FeJ mouse model, but has the advantage of consistent and reproducible progression towards necrotic hypoxic 
lesions in all infected mice. M. tuberculosis infection of C3HeB/FeJ mice induces three distinct types of lesions: 
large patient-like lesions (Type I), rapidly progressive granulocytic lesions mainly composed of neutrophils (Type 
II) and small cellular inflammatory lesions (Type III, ‘BALB/c-type’)18. The heterogeneous distribution of lesion 
types and their differential responses to chemotherapy, as well as the early mortality of mice predominantly suf-
fering from Type II lesions, remain major challenges of the C3HeB/FeJ mouse model of TB14. Type I lesions in 
C3HeB/FeJ mice were reported to develop liquefaction and even cavitation of necrotic lesions13, two pathological 
end-stage correlates of human TB that were not observed in Nos2−/− mice before termination of our experiments 
at 84 days after infection (Supplementary Fig. S1). At this late stage of infection, a layer of infected foamy mac-
rophages located on the inner side of the fibrotic capsule constitutes the interface between the cellular and caseous 
regions as seen in human granulomas26 (Fig. 2). Foamy macrophages harbour large quantities of lipids including 
cholesterol41 and presumably undergo necrosis thereby contributing lipids to the caseous centre. Cholesterol is 
likely one of the major carbon sources of mycobacteria during infection as suggested by transcriptome data42.
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The primary aim of the current study was to evaluate the suitability of Nos2−/− mice for TB drug develop-
ment. Analysis of pathology over time revealed that lung lesions were homogeneously distributed and consist-
ently developed central necrosis and hypoxia. Because the time window for onset of patient-like pathology is 
well defined between 42 and 56 days post-infection, we initiated drug administration at 42 days in the control 
group and at 56 days in the study group to specifically determine the impact of hypoxic necrotizing lesions on 
the outcome of monotherapy (Fig. 1a). A panel of nine drugs, either in clinical use or under clinical develop-
ment was chosen for which efficacy data in humans or animal models are already available. The first-line TB 
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Figure 4. Impact of monotherapy on pulmonary pathology in Nos2−/− mice with TB. Monotherapy for 4 
weeks was initiated at day 42 (control group) or after onset of central necrosis and hypoxia in lung lesions 
at day 56 (study group) as described in Fig. 1a. Drugs were administered by oral gavage on 6 days per week. 
Consecutive thin sections of the formalin-fixed paraffin-embedded entire left lung lobe were stained with H&E 
or the pimonidazole hypoxia detection method and analyzed microscopically. One representative dataset out 
of 2 independent experiments is shown. Data were analyzed using two-way ANOVA with multicomparison 
and Tukey’s post-test. Shown are means ± s.e.m. and statistical significance as compared to the control group 
prior to drug treatment, n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (a) isoniazid, 25 mg/kg. (b) 
rifampin, 10 mg/kg and 20 mg/kg; rifapentine, 5 mg/kg and 10 mg/kg. Statistical significance for different doses 
of the same drug at respective time points was similar and was only plotted once. (c) metronidazole, 400 mg/
kg. (d) pretomanid, 75 mg/kg. (e) delamanid, 1 mg/kg. (f) linezolid, 100 mg/kg. (g) moxifloxacin, 200 mg/kg. (h) 
BTZ043, 50 mg/kg.
www.nature.com/scientificreports/
7SCIENTIFIC RepoRts | 7: 8853  | DOI:10.1038/s41598-017-09177-2
bacterial burden in lungs remained constant indicating the presence of drug-tolerant M. tuberculosis as validated 
by absence of genetic drug resistance after plating organ homogenates on agar supplemented with INH. It is 
tempting to speculate that the drug-tolerant subpopulation might be in a non-replicating state during which sus-
ceptibility to the cell wall inhibitor INH is lost. Evidence is increasing that bacterial persistence is a state actively 
maintained by a pool of intracellular stress responses allowing for prompt adaptation43. Whether INH-induced 
persistence of Mtb in Nos2−/− mice compares to classic non-replicating survival described in culture models27, 28 
or indeed is actively maintained44 will be addressed in the context of our future work evaluating TB multi-drug 
regimens in the Nos2−/− model.
The rifamycins RIF and RPT showed strongest bactericidal activity among all drugs tested in our experiments. 
RPT was more potent prior to the onset of necrosis and hypoxia, whereas both drugs demonstrated comparable 
efficacy once patient-like pathology had established itself (Fig. 3b). Other murine models have suggested that 
RPT has roughly a 4-fold greater potency than RIF15. Our experiments indicate that hypoxic necrotizing lesions 
of Nos2−/− mice render RIF more potent but do not affect RPT efficacy (Fig. 3b). Intriguingly, RIF has been found 
to accumulate in the caseum of human TB lesions over time21. This could explain its increased efficacy in our 
experiments. In turn this would imply that RPT does not accumulate in lesions of Nos2−/− mice or in patients, 
which remains to be verified experimentally. Thus, performance of RIF and RPT in the Nos2−/− model closely 
mimics clinical outcome8.
Gradual oxygen depletion or nutrient starvation induces a state of non-replicating drug tolerance in M. tuber-
culosis27, 28. Moreover, oxygen limitation renders M. tuberculosis susceptible to high concentrations of MTZ, which 
may not be achievable in humans at a sustainable level28. The drug was moderately active in late-stage TB lesions 
in Nos2−/− mice (Fig. 3c) indicating that a hypoxic non-replicating subpopulation resides in advanced caseous 
lesions. MTZ is active against M. bovis in rabbits7 and nonhuman primates45. Except for the late chronic stage 
of TB in BALB/c mice this drug lacks demonstrable activity in murine models including C3HeB/FeJ mice13, 46. 
MTZ may have led to earlier sputum smear and culture conversion in a clinical trial but was too neurotoxic for 
long-term use47. Two newer nitroimidazoles, PTM and DLM exhibit mycobactericidal activity both in growing 
and in hypoxic non-replicating bacilli and hence are more promising candidates against M. tuberculosis48. DLM 
has been approved for patients with multidrug resistant TB and PTM is currently undergoing late stage clinical 
development. Both drugs expressed comparable activity in hypoxic necrotizing lesions of Nos2−/− mice (Fig. 3d,e) 
supporting their further evaluation.
The drug candidate, LZD, with demonstrable efficacy in extensively drug-resistant TB patients38, reduced 
the M. tuberculosis load in lungs of Nos2−/− mice prior to onset of necrosis and hypoxia and was bacteriostatic 
thereafter (Fig. 3f). Surprisingly this drug reduced occurrence of lung lesions including necrosis and completely 
abolished hypoxia (Fig. 4f). LZD has been shown to have immunomodulatory and anti-inflammatory effects49, 50, 
which may have supported pathologic alterations observed in our experiments. In C3HeB/FeJ mice a linear 
reduction of the bacterial burden in lungs over 8 weeks of LZD monotherapy was observed originally13. Using 
larger experimental groups, however, it was found that C3HeB/FeJ mice segregate into two groups of LZD 
responders either showing reduced c.f.u. in lungs similar to BALB/c mice or revealing a bacteriostatic profile14. 
Our results are comparable to the latter group of C3HeB/FeJ mice likely characterized by large caseous necrotic 
lesions18.
In general, MFX was strongly bactericidal in Nos2−/− mice, but roughly 10-fold less effective after onset of 
necrosis and hypoxia (Fig. 3g). Reduced activity was likely caused by insufficient lesion penetration of the drug 
as demonstrated in TB patients21. Several clinical trials to evaluate new TB drugs and treatment regimens have 
generated disappointing results8–10. The REMox TB trial, one of the largest clinical studies in the field, assessed 
whether replacement of INH or EMB in the standard regimen RIF/INH/EMB/PZA by the DNA-gyrase inhibitor 
MFX could shorten treatment time to 4 months. This trial was based on promising results from various murine 
models51–53 and on clinical data indicating a moderately higher rate of sputum conversion when EMB or INH 
were substituted by MFX54–58. Although initial murine studies failed to predict the clinical outcome of shorter 
MFX treatment time, carefully designed mouse experiments mimicked clinical results, underscoring the value 
of appropriately designed small rodent models for TB drug development59. TB drug testing in C3HeB/FeJ mice 
and new insights into drug penetration of TB lesions in patients and rabbits led to the conclusion that animal 
models showing patient-like TB pathology are key in overcoming the disconnect between pre-clinical and clinical 
studies60. In contrast to MFX, BTZ043 possessed consistent potency in Nos2−/− mice regardless of pulmonary 
pathology (Fig. 4h) suggesting uniform tissue distribution and sufficient lesion penetration. The profound bac-
tericidal activity of BTZ043 in the Nos2−/− model, ranging between the most potent TB first-line drugs, INH and 
RIF, warrants further investigation of this and related benzothiazinones61.
In conclusion, unlike other murine models, Nos2−/− mice with patient-like pathology in principle correctly 
predicted clinical outcomes of RIF/RBT8, MTZ47, MXF9, 10, and potentially LZD38 (Supplementary Table S1). 
Results obtained for PTM, DLM and BTZ043 in Nos2−/− mice support development and consideration of these 
drugs for standard TB chemotherapy. Note that drugs interfering with host NO production or requiring acti-
vation by NO may not be suitable for testing in Nos2−/− mice due to their inability to produce NO in immune 
cells, which represents a limitation of this model. The development of new drugs and regimens for shortening 
the treatment of TB requires understanding the impact of specific drugs on specific types of lesions coexisting in 
patients. TB lesions in humans are very complex and often form a continuum of multiple discrete types of pathol-
ogies ranging from pneumonic infiltrates to dense consolidations to cavitation. No single model will suffice for 
understanding the impact of a new drug or regimen on all these types of pathologies. Yet, the Nos2−/− mouse with 
a patient-like pathology of lung granulomas and uniform disease progression provides a highly consistent and 
predictive model for this crucial type of pathology in TB drug development.
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Methods
Bacterial strains and growth conditions. M. tuberculosis H37Rv (American Type Culture Collection, 
#27294) was grown in Middlebrook 7H9 broth (Becton Dickinson) supplemented with albumin-dextrose-cat-
alase enrichment (Becton Dickinson), 0.2% glycerol, 0.05% Tween 80 or on Middlebrook 7H11 agar (Becton 
Dickinson) containing 10% v/v oleic acid-albumin-dextrose-catalase enrichment (Becton Dickinson) and 0.2% 
glycerol. Infection stocks were prepared from mid-log phase cultures. For c.f.u. determinations, serial dilutions 
were performed in PBS/0.05% Tween 80 and plated onto Middlebrook 7H11 agar. Plates were incubated at 37 °C 
for 3–4 weeks prior to c.f.u. counting.
Animal experiments. Female C57BL/6 Nos2−/− mice were bred in-house and maintained under specific 
pathogen-free conditions. Eight- to ten-week-old animals were anesthetized (ketamine 65 mg/kg, acepromazine 
2 mg/kg, xylazine 11 mg/kg) and infected by injecting 1,000 c.f.u. of M. tuberculosis in 20 μl PBS into the ear 
dermis. At 14 and 21 days post-infection each mouse received 0.5 mg of monoclonal anti-tumour necrosis fac-
tor alpha antibody (purified from MP6-XT22 cultures) by i.p. injection. Two hours before euthanasia animals 
received 60 mg/kg pimonidazole hydrochloride i.p. to allow for detection of hypoxic regions in organ sections.
Ethical statement. All animal studies have been ethically reviewed and approved by the State Office for 
Health and Social Services, Berlin, Germany. Experimental procedures were carried out in accordance with the 
European directive 2010/63/EU on Care, Welfare and Treatment of Animals.
Drugs, formulations and administration. INH, LZD, RIF, RPT, MXF and MTZ were purchased from 
Sigma and formulated in 0.4% methylcellulose. Rifamycins were dissolved in dimethyl sulfoxide prior dilution 
in 0.4% methylcellulose. The final concentration of dimethyl sulfoxide did not exceed 5%. BTZ04340, PTM and 
DLM62, 63 were synthesized in-house and formulated in 0.25% carboxymethyl cellulose/0.05% Tween 80 (BTZ043) 
or in 10% hydroxypropyl-β-cyclodextrine/10% lecithin (PTM, DLM)35, 64. Drug formulations stored at 4 °C were 
administered in 0.2 ml per dose by oral gavage for 6 days per week.
Staining procedures and histopathology. The left lung lobe of mice was fixed using 4% paraformalde-
hyde in PBS and embedded in paraffin. Organ sections (2–3 μm) were deparaffinised and subjected to haematox-
ylin and eosin (H&E) staining, Trichrome staining (Sigma), hypoxia staining (Hypoxyprobe-1 kit, Hypoxyprobe 
Inc.) or Ellis staining (Sigma) to visualize acid-fast bacilli in tissues; staining was performed according to the 
manufacturer’s instructions. Tissue sections were analysed using a Zeiss Axio Imager Z1 with CCD AxioCam. A 
researcher blinded to the study groups scored 16 individual stained sections of each organ in study groups of five 
mice per time point. Central necrosis of lesions was defined as a lighter pink region indicating tissue consolida-
tion surrounded by granulomatous inflammatory infiltrate. Lesions were considered hypoxic when pimonidazole 
adducts in their central region could be visualized by a brown stain.
Bacterial burden of mouse lungs and drug-resistant colonies. Mice were euthanized at dedicated 
time points and superior, middle inferior and post-caval lobes were removed and homogenized in 1 ml PBS/0.05% 
Tween 80. Serial dilutions of organ homogenates were plated onto Middlebrook 7H11 agar and in addition on 
agar supplemented with 0.4% activated charcoal for all time points during chemotherapy. Plates showing higher 
c.f.u. counts were used for data analysis. To determine the level of drug resistance at the last time point of each 
experiment, ¼ of the lung homogenate was plated onto Middlebrook 7H11 agar containing 4 μg/ml INH, 0.4 μg/
ml RIF, 0.4 μg/ml RPT or 8 μg/ml LZD. Plates were examined after 4 weeks of incubation at 37 °C and kept until 
week 8 for re-examination. The limit of detection for drug-resistant colonies was 4 c.f.u. per organ.
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